CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that it
will host a key opinion leader (KOL) breakfast symposium focused on the
unmet need, treatment landscape and opportunities for selective
cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast
cancers on Wednesday, April 24, 2019 from 8:30 – 10:30 a.m. ET in New
York City. Syros is currently evaluating SY-1365, a first-in-class
selective CDK7 inhibitor, in a Phase 1 clinical trial as a single agent
and in combination with other therapies in multiple ovarian and breast
cancer patient populations.
The event will feature presentations from Dejan Juric, M.D., Medical
Oncologist and Director at the Termeer Center for Targeted Therapies,
Massachusetts General Hospital and Charles A. Leath, III, M.D.,
M.S.P.H., Professor in the Division of Gynecologic Oncology and Ellen
Gregg Shook Culverhouse Chair in Gynecologic Oncology at the University
of Alabama Medical Center. Additionally, members of the Syros management
team will provide an overview of SY-1365, including preclinical and
clinical data supporting its ongoing development in ovarian and breast
cancer patients, and SY-5609, its oral selective CDK7 inhibitor, which
is expected to enter a Phase 1 oncology study in early 2020.
A live webcast of the event will be available on the Investors & Media
section of the Syros website at www.syros.com.
An archived replay of the webcast will be available for approximately 30
days following each presentation.
About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding regulatory region of the genome to
advance a new wave of medicines that control the expression of genes.
Syros has built a proprietary platform that is designed to
systematically and efficiently analyze this unexploited region of DNA to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros’ gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros’
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1
clinical trial focused on patients with ovarian and breast cancers.
Syros is also developing a deep preclinical and discovery pipeline,
including SY-5609, an oral CDK7 inhibitor, as well as programs in
immuno-oncology and sickle cell disease. Led by a team with deep
experience in drug discovery, development and commercialization, Syros
is located in Cambridge, Mass.